News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kalypsys, Inc. Initiates Phase IIa Clinical Trial of Topical iNOS Inhibitor


12/18/2007 2:13:37 PM

SAN DIEGO--(BUSINESS WIRE)--Kalypsys Inc. today announced the initiation of a Phase IIa clinical trial of KD7040, an inducible nitric oxide synthase (iNOS) inhibitor formulated as a topical gel, for the treatment of postherpetic neuralgia (PHN).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES